Top Markets
Coin of the day
Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.

ZYNE
Classement en actions #26763
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in... Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
Prix de l'action
$1.30
Dernière synchronisation: 2023-10-13
Capitalisation boursière
$38.02M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Zynerba Pharmaceuticals, Inc. (ZYNE)

Catégorie

Ratio P/S pour Zynerba Pharmaceuticals, Inc. (ZYNE)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Zynerba Pharmaceuticals, Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Zynerba Pharmaceuticals, Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes